We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Austrian Patent Office Upholds Lipitor Patent

Law360 (October 17, 2006, 12:00 AM EDT) -- Pfizer Inc. has won yet another battle in its war against Ranbaxy Laboratories over its generic version of blockbuster cholesterol drug Lipitor, after the Austrian Patent Office upheld Pfizer’s basic patent for the drug.

The APO ruled that Ranbaxy’s generic version would infringe Pfizer’s patents for atorvastatin, the active ingredient in Lipitor, which in Austria is sold under the name Sortis.

Pfizer said that it would continue to take action against Ranbaxy to prevent the launch of a generic version of Lipitor before the patents expire...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.